Maintenance chemotherapy for ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Chen, Hui ^a   Fang, Fang ^a   Liu, Guan J ^b   Xie, Huan Yu ^c   Zou, Juan ^a   Feng, Dan ^d  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c PEOPLE S HOSPITAL OF DEYANG CITY   (China)

^d CHENGDU WOMEN S AND CHILDREN S CENTRAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

ABDOMINAL RADIOTHERAPY; ANEMIA; CANCER RADIOTHERAPY; DIARRHEA; HUMAN; INTESTINE OBSTRUCTION; MAINTENANCE CHEMOTHERAPY; MAINTENANCE RADIOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PATHOLOGICAL COMPLETE REMISSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECTUM HEMORRHAGE; REMISSION; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING; DISEASE FREE SURVIVAL; FEMALE; META ANALYSIS; METHODOLOGY; MORTALITY; OVARY TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); OVARIAN NEOPLASMS;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; OVARIAN NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891669660     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007414.pub3     Document Type: Review

References (39)

1. Bolis G, Danese S, Tateo S, Rabaiotti E, D'Agostino G, Merisio C, et al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer:results from a phase IIstudy. International Journal of Gynecology Cancer 2006;16(suppl 1):74-8.
2. Cheng NH, Huang HF, Pan LY, Shen K, Wu M, Yang JX. Consolidation chemotherapy in advanced epithelial ovarian carcinoma:a prospective randomized controlled trial. Medical Journal of Chinese People's Liberation Army 2006;31(7):654-6.
3. Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, et al. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecology Oncology 2011;122(1):89-94.
4. Nicoletto MO, Tumolo S, Falci C, Donach M, Visona E, Rosabian A, et al. A randomized study of epithelial ovarian cancer: Is chemotherapy useful after complete remission?. International Journal of Medical Sciences 2004;1(2):116-25.
5. Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, et al. After 6 Italian Cooperative Group. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. Journal of Clinical Oncology 2009;27(28):4642-8.
6. Piccart MJ, Floquet A, Scarfone G, Willemse PHB, Emerich J, Vergote I, et al. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase 3 study in ovarian cancer patients with a pathologically complete remission after platinumbased intravenous chemotherapy. International Journal of Gynecologic Cancer 2003;13(suppl 2):196-203.
7. Placido SD, Scambia G, Vagno GD, Naglieri E, Lombardi VA, Biamonte R, et al. Toptecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. Journal of Clinical Oncology 2004;22(13):2635-42.
8. Sorbe B. Consolidation treatment of advanced (FIGO stage 3) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. International Journal of Gynecologic Cancer 2003;13(3):278-86.
9. Abaid LN, Goldstein BH, Micha JP, Rettenmaier MA, Brown JV, Markman M. Improved overall survival with cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology 2010;78(5-6): 389-93.
10. Bois A, Floquet A, Kim JW, Rau J, Campo JM, Friedlander M, et al. Incorporation of Pazopanib in maintenance therapy of ovarian cancer. Journal of Clinical Oncology 2014; 32(30):3374-87.
11. Cure H, Battista C, Guastalla JP, Fabbro M, Tubiana- Mathieu N, Bourgeois H, et al. Phase 3 randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC/Italy study. Proceedings of American Society of Clinical Oncology. 2001.
12. Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD, et al. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followedby paclitaxel consolidation in ovarian cancer. Gynecologic Oncology 2011; 123:479-85.
13. Lee SJ, Lee JW, Min JA, Park CS, Kim BG, Lee JH, et al. A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum inepithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy. International Journal of Gynecological Cancer 2006;16(1):95-100.
14. Lesnock JL, Farris C, Krivak TC, Smith KJ, Markman M. Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer. Gynecology Oncology 2011;122(3): 473-8.
15. Mannel R, Brady M, Kohn E, Hanjani P, Hiura M, Lee R, et al. Gynecologic Oncology. Conference: 41st Annual Meeting of the Society of Gynecologic Oncologists, SGO San Francisco, CA United States. March 2010; Vol. 116: S2.
16. Markman M, Liu PY, Wilczynski S, Mank B, Copeland LJ, Alvarez RD, et al. Phase 3 randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial. Journal of Clinical Oncology 2003;21(13):2460-5.
17. Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: followup of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecology Oncology 2009; 114(2):195-8.
18. Scarfone G, Merisio C, Garavaglia E, Richiardi G, Tateo S, D'Agostino S, et al. A phase 3 trial of consolidation versus NIHL (NIL) for advanced epithelial ovarian cancer (AEOC) after complete remission (CR). Proceedings of American Society of Clinical Oncology. 2002.
19. Suidan RS, Clair CM, Lee SJ, Barlin JN, Roche KL, Tanner EJ, et al. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advancedovarian cancer. Gycecologic Oncology 2014;134(3):468-72.
20. NCT00108745. Paclitaxel or polyglutamate paclitaxel or observation in treating women with stage III or stage IV ovarian epithelial or peritoneal cancer. http://clinicaltrials.gov/show/NCT00108745.
21. Bertelsen K, Jakobsen A, Strøyer J, Nielsen K, Sandberg E, Andersen JE, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecologic Oncology 1993;49(1):30-6.
22. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base 2004; 2004; Vol. (No.5. version 2.0).
23. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 27/11/2017.
24. Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide doxorubicin and cisplatin in advanced ovarian carcinoma. Gynecologic Oncology 1992;45 (3):284-8.
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
26. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 updated March 2011]. The Cochrane Collaboration, Available from www.cochrane-handbook.org.
27. Kikuchi Y, Kita T, Takano M, Kudoh K, Yamamoto K. Treatment options in the management of ovarian cancer. Expert Opinion on Pharmacotherapy 2005;6(5):743-54.
28. Lambert HE, Rustin GJS, Gregory WM, Nelstrop AE. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. Annals of Oncology 1997;8:327-33.
29. Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schunemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;23 (2):81.
30. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82.
31. Ozols RF. Maintenance chemotherapy standard care. American Society of Clinical Oncology. 2004.
32. Ozols RF. Challenges for chemotherapy in ovarian cancer. Annals of Oncology 2006;17(suppl.5):181-7.
33. Poveda A. Ovarian cancer treatment: what is new. International Journal of Gynecologic Cancer 2003;13(suppl 2):241-50.
34. Stuart GCE. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecologic Oncology 2003;90:8-15.
35. Thigpen T. First-line therapy for ovarian carcinoma: What's next?. Cancer Investigation 2004;22(suppl 2):21-8.
36. Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD. Intraperitoneal radioactive phosphorus (32P) versus observation after negative secondlook laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. Journal of Clinical Oncology 2003;21:2849-55.
37. Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database of Systematic Reviews 2010, Issue 9. DOI: 10.1002/14651858.CD007414.pub2
38. Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 6. DOI: 10.1002/14651858.CD007414.pub3
39. Mei L, Fang F, Wei DM, Chen H, Liu GJ, Xie HY, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database of Systematic Reviews 2008, Issue 4. DOI: 10.1002/14651858.CD007414